Government spend £9.2 billion on private healthcare providers for NHS in 2018-19

pharmafile | July 22, 2019 | News story | Sales and Marketing DHSC, NHS, UK, health, healthcare, politics, private providers 

The Department of Health and Social Care paid £9.2 billion to private providers in the year prior to 31 March 2019, according to their annual report.

The 14% increase comes as health secretary Matt Hancock pledged to reduce the outsourcing of patient care. “There is no privatisation of the NHS on my watch,” Hancock said to MPs and health chiefs in January 2019.

Shadow health and care secretary Jonathan Ashworth commented: “Tory privatisation of our NHS continues to gather pace with public expenditure on independent providers now at a record high. These accounts blow apart Matt Hancock’s claims to parliament there would be no privatisation on his watch.”

Dr John Lister, a health policy academic and secretary of the campaign group Keep Our NHS Public added: “The extra £415m spent on private providers in the last year is a significant 5% increase and makes a nonsense of Matt Hancock’s pledge of ‘no privatisation on my watch’. The full picture is much more alarming with the added prospect of a Johnson government putting the NHS ‘on the table’ in any future US trade negotiations.”

Paul Evans, the director of the NHS Support Federation, said: “In response to criticism, failures and waste, the health secretary promised no further privatisation. But since then the outsourcing of NHS services has rolled on and more services have become reliant on the private sector to deliver their core service.”

A DHSC spokesperson said: “We are committed to a world-class NHS free at the point of use. The proportion of NHS funding going to independent sectors has remained largely stable since 2014-15. The overall funding in the NHS has increased since 2014-15, so while the proportion of spend has not changed, the amount spent has risen in both public and independent sectors.”

“We want patients to receive the best quality of care possible and the vast majority is provided by the NHS, supported by independent organisations when a local doctor decides it is in their patients’ best interests.”

Louis Goss

Related Content

Novo Nordisk launches Wegovy in the UK

Novo Nordisk has today announced that Wegovy (semaglutide injection) is now available in the UK …

Bristol Myers Squibb’s Sotyktu recommended for NHS use for adult patients with psoriasis

Bristol Myers Squibb (BMS) has announced that the National Institute for Health and Care Excellence …


UK plans £40m drug trial for Novo Nordisk’s Wegovy to aid NHS in treating obesity

The UK Government has announced plans to launch a pilot programme which will provide GPs …

Latest content